Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E. Reustle A, et al. Among authors: stuhler v. Genome Med. 2020 Mar 30;12(1):32. doi: 10.1186/s13073-020-00731-8. Genome Med. 2020. PMID: 32228647 Free PMC article.
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A, Menig LS, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M, Schaeffeler E. Reustle A, et al. Among authors: stuhler v. Clin Transl Med. 2022 Jun;12(6):e883. doi: 10.1002/ctm2.883. Clin Transl Med. 2022. PMID: 35678045 Free PMC article.
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, Schaeffeler E. Büttner FA, et al. Among authors: stuhler v. Genome Med. 2022 Sep 15;14(1):105. doi: 10.1186/s13073-022-01105-y. Genome Med. 2022. PMID: 36109798 Free PMC article.
p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics.
Diesing K, Ribback S, Winter S, Gellert M, Oster AM, Stühler V, Gläser E, Adler F, Hartwig C, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, Kroeger N. Diesing K, et al. Among authors: stuhler v. J Cancer Res Clin Oncol. 2021 Dec;147(12):3565-3576. doi: 10.1007/s00432-021-03786-1. Epub 2021 Sep 9. J Cancer Res Clin Oncol. 2021. PMID: 34499221 Free PMC article.
Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC.
Ribback S, Winter S, Klatte T, Schaeffeler E, Gellert M, Stühler V, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, Kroeger N. Ribback S, et al. Among authors: stuhler v. World J Urol. 2022 Mar;40(3):739-746. doi: 10.1007/s00345-021-03900-5. Epub 2021 Dec 2. World J Urol. 2022. PMID: 34859284 Free PMC article.
Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma.
Sauter-Meyerhoff C, Bohnert R, Mazzola P, Stühler V, Kandabarau S, Büttner FA, Winter S, Herrmann L, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Ossowski S, Bedke J, Schwab M, Schaeffeler E. Sauter-Meyerhoff C, et al. Among authors: stuhler v. Cancers (Basel). 2021 Dec 10;13(24):6221. doi: 10.3390/cancers13246221. Cancers (Basel). 2021. PMID: 34944839 Free PMC article.
36 results